Novel Blood-based Transcriptional Biomarker Panels Predict the Late-Phase Asthmatic Response

Abstract

Interestingly, the biomarker panel containing novel transcripts successfully validated compared with panels with known, well-characterized genes. These biomarker-blood tests may be used to identify subjects with asthma who develop the LAR, and may also represent members of novel molecular mechanisms that can be targeted for therapy.